With Pataday Extra Strength, Alcon Eyes Consumers Looking For OTC 24-Hour Eye Allergy Remedy

Pataday Once Daily Relief Extra Strength is the same formulation as Novartis' Rx Pazeo. It will be the first OTC eye drop indicated for allergy itch with 24-hour efficacy, available online in September and through retailers in early 2021.

Pataday once daily relief Eye allergy itch relief
Pataday Once Daily Relief Extra Strength (olopatadine 0.7%) indicated for ocular allergies is the third product available under the Pataday OTC brand Alcon Labs launched earlier in 2020 with Once Daily Relief (0.2%) and Twice Daily Relief (0.1%).

Alcon Laboratories Inc. positions its third olopatadine eye drop formulation approved for an Rx-to-OTC switch in the US in 2020 as an ocular allergy remedy for consumers who need 24-hour doses.

The US division of Swiss firm Alcon Inc. on 13 July announced Pataday Once Daily Relief Extra Strength (olopatadine...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Rx-to-OTC Switch

HI-Health (Free-1): Why Children with ADHD Hate Bedtime: Solutions to ADHD Sleep Problems

 
• By 

Children with ADHD often struggle with bedtime due to restless minds, difficulty winding down, and heightened sensitivity to nighttime distractions. This article explores the reasons behind these sleep challenges and offers practical solutions.

US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks

 
• By 

Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process. 

Perrigo’s Consumer Health Brand Talk Gets An Executive Voice With First Brand Chief Appointed

 

David Ball moves from Bayer’s North America business to be Perrigo’s first chief brand and digital officer. He joins CEO who also moved to Perrigo from Bayer with decades of branded product experience.

WHO Resolution Targets OTC Antimicrobials, Industry Insists Problem Is Rx Misuse

 
• By 

A draft declaration to be presented to the UN General Assembly in September suggests that a “lack of regulation of over-the-counter use of antimicrobials” is one of the “drivers of antimicrobial resistance.” Industry, however, insists that misuse and over-prescription of antibiotics are the primary drivers of AMR, and is advocating for the text to be amended accordingly. 

More from Health

HI-Health-Premium: ‘Data Article’ article that includes different Composer content

 
• By 

To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.

US and Canada to expand review partnership - Clone article

 

A pilot partnership between the FDA and Canada's Medical Devices Programme has been so successful the two agencies will talk this week about how to expand it.

Different Name, Same Contamination, Recall Problems For US Homeopathic Nasal Spray Firm

Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.